RT Journal Article
SR Electronic
T1 TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e004991
DO 10.1136/jitc-2022-004991
VO 10
IS 7
A1 Rosen, David B
A1 Kvarnhammar, Anne Månsson
A1 Laufer, Burkhardt
A1 Knappe, Thomas
A1 Karlsson, Jens Jakob
A1 Hong, Enping
A1 Lee, Yu-Chi
A1 Thakar, Dhruv
A1 Zúñiga, Luis Alejandro
A1 Bang, Kathy
A1 Sabharwal, Simran Singh
A1 Uppal, Karan
A1 Olling, Janne Damm
A1 Kjaergaard, Kristian
A1 Kurpiers, Thomas
A1 Schnabel, Meike
A1 Reich, Diana
A1 Glock, Philipp
A1 Zettler, Joachim
A1 Krusch, Mathias
A1 Bernhard, Ana
A1 Heinig, Stefan
A1 Konjik, Valentino
A1 Wegge, Thomas
A1 Hehn, Yvonne
A1 Killian, Steffen
A1 Viet, Laura
A1 Runz, Josefine
A1 Faltinger, Frank
A1 Tabrizi, Mohammad
A1 Abel, Kristin Laura
A1 Breinholt, Vibeke Miller
A1 Singel, Stina M
A1 Sprogøe, Kennett
A1 Punnonen, Juha
YR 2022
UL http://jitc.bmj.com/content/10/7/e004991.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.